The most recent challenge in supply chain has been in redefining how patients engage with providers, forcing the industry to adapt the way they recruit, engage and manage them throughout the process. The rapid consumerization of clinical trials has had a growing impact on patient preferences.
How does this all relate to decentralized clinical trials (DCTs), and what has been the impact of COVID-19 in this trend? Without a doubt, COVID has increased the adoption of DCTs. DCTs were not new, but the trend towards decentralization was certainly accelerated by the pressure generated by COVID on patient access and the continuation of clinical trials. The Pfizer BioNTech COVID vaccine development utilized decentralized methodologies, with over 90 percent of that trial’s monitoring conducted remotely.
While patient-centricity has always been key in clinical trials, whether observational or interventional, DCTs magnify this focus on the patient and their participation. Enabling the patient to participate in a way that is not onerous or overly challenging — whether through convenience or health factors — has a significant impact on:
- patient recruitment
- patient retention and
- the speed to successful progression and outcome of a clinical trial
This benefits investigators, the industry and importantly, future beneficiaries.
Moving some trial site activities away from the traditional site, often into patients’ homes (frequently their preferred location), has been shown to increase recruitment by 60 percent or more, and it typically maintains patient retention at over 90 percent.
Join the featured speaker in exploring this behavioral shift in the industry, as well as how consumer-led/ originated technologies and customer experiences in a consumer environment are driving patient expectations in clinical trial participation — and how these present challenges to the supply chain. The webinar will also examine the link between customer experience and consumerization within clinical trials:
- How the accelerative impact of COVID-19, emerging technology and consumerization has changed patients’ behavior, preferences and expectations of technology in a clinical trial environment
- Achieving patient-centricity is often cited as a key to success:
- What are the technological links between consumerization, patient-centricity and optimizing speed and quality in clinical trials?
- How has consumerization of clinical trials impacted patient recruitment, engagement and management?
Join this webinar to learn how the supply chain can collaborate to meet patients’ expectations across decentralized clinical trials.
Mac Winslow, Senior Director, Clinical Services, Avantor
Mac Winslow is the Senior Director of Global Customer Development for Clinical Services at Avantor, which maximizes clinical trial efficiencies across the globe, providing scalable, end-to-end service capabilities including biorepository and sample management, custom kitting and clinical trial equipment and ancillary solutions. Mac has more than 20 years of sales experience, including a decade of specialization in biorepository services and sample management sales. Prior to joining Avantor, Mac spent eight years at BioStorage Technologies, Inc., where he oversaw North American and European sales teams. Mac earned a BS in Agricultural Business Management from North Carolina State University.Message Presenter
Who Should Attend?
- Clinical Trials/Study Management – Director/Manager/Lead
- Clinical Operations – Director/Manager/Lead
- Research Operations – Director/Manager/Lead
- Preclinical/Non-clinical research
- Clinical Development/Research
- Samples Management/Logistics – Biorepository/Samples/Biosamples/Archivist
What You Will Learn
Attendees will learn the following key takeaways:
- Trials are considered decentralized when they include specific products and services that enable elements of the trial to be conducted away from the traditional “centralized” site location
- DCT (decentralized clinical trial) represents 15 percent of the market today, moving to 17 percent in the future
- Market for digital DCT solutions has boomed since the start of the pandemic, remaining dynamic, with a rapid growth forecast
- The patient is at the heart of decentralization — and digitization plays a crucial part in that patient-centric approach to clinical trials — and to the operational efficiency and eventually the outcome of the trial.
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development, and production activities in the industries we serve. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For more information, visit avantorsciences.com and find us on LinkedIn, Twitter and Facebook.